Rainer Riedl

Abstract: Abstract Finding strategies against the development of antibiotic resistance is a major global challenge for the life sciences community and for public health. The past decades have seen a dramatic worldwide increase in human‐pathogenic bacteria that are resistant to one or multiple antibiotics. More and more infections caused by resistant microorganisms fail to respond to conventional treatment, and in some cases, even last‐resort antibiotics have lost their power. In addition, industry pipelines for the development of novel antibiotics have run dry over the past decades. A recent world health day by the World Health Organization titled “Combat drug resistance: no action today means no cure tomorrow” triggered an increase in research activity, and several promising strategies have been developed to restore treatment options against infections by resistant bacterial pathogens.

TL;DR: In this article, the authors highlight the most recent and promising techniques aimed at the improvement of the oral bioavailability of peptides, which will influence future approaches of pharmaceutical companies in the development of new, more efficient, and safer orally delivered peptides.

TL;DR: According to the present invention there is provided a compounds of formula (I): and pharmaceutically acceptable salts thereof as mentioned in this paper, and they are provided a compound of formula I:

TL;DR: The structure-based design of superior MMP inhibitors highlights the power of this technique and displays strategies for the development of treatment options based on the modulation of challenging drug targets.